Finally, after 2 decades of being an approved drug, 3 new structures are available
Boehringer Ingelheim (Germany) has recognized the potential of Electron Diffraction and its efficiency in drug development, even after nearly 20 years of having a patented drug compound. By using our technology and the ELDICO ED-1 device, they successfully determined the crystalline structures of three polymorphs of the same drug compound. Until now, no structural data was available, as other existing methods had failed to achieve this.
The three crystalline samples analysed were composed of very tiny "hair-like" needle shape crystals.
Electron diffraction experiments on these crystalline forms, were successful and 3 new structures of this drug compound have been recently reported by BI.
Would you like to learn how ELDICO Scientific,
download the published paper 👉
After submitting the form, you will receive an email with a link to download the paper.
ELDICO Scientific AG, "The Electron Diffraction Company," stands at the forefront of Swiss technology and innovation. Established in 2019, ELDICO is dedicated to advancing scientific exploration with its groundbreaking electron diffractometer. This pioneering device empowers researchers to unravel the mysteries of the nanoscale world, providing precise answers to their inquiries. Through the development, production, and sale of this cutting-edge technology, ELDICO is shaping the future of particle analysis and driving progress in scientific discovery.
In 2022, ELDICO Scientific opened its Experience Centre for electron diffraction in Basel, Switzerland, showcasing its cutting-edge device, the ELDICO ED-1. Nestled within the Switzerland Innovation Park Basel, this center provides an exclusive platform for customers to delve into the world of electron diffraction. Here, they can access a range of services, including contract research, scientific application development, collaborative opportunities, and tailored training workshops. Our clientele primarily comprises researchers from industrial and R&D-intensive sectors, particularly in burgeoning fields such as pharmaceuticals, energy storage, and advanced materials.